Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 250

1.

Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW, Liewehr DJ, Steinberg SM, Brogi E, Akram MM, Killian JK, Edelman DC, Pineda M, Scurci S, Degenhardt YY, Laquerre S, Lampkin TA, Meltzer PS, Camphausen K, Steeg PS, Palmieri D.

Clin Exp Metastasis. 2011 Dec;28(8):899-908. doi: 10.1007/s10585-011-9421-9. Epub 2011 Sep 21.

PMID:
21953073
[PubMed - indexed for MEDLINE]
2.

Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.

Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, Hughes A, Moy C, Liu-Sullivan N, Powers S, Bachman K, Jackson J, Weber B, Wooster R.

Mol Cancer Ther. 2010 Jul;9(7):2079-89. doi: 10.1158/1535-7163.MCT-10-0095. Epub 2010 Jun 22.

PMID:
20571075
[PubMed - indexed for MEDLINE]
Free Article
3.

Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.

Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.

Cancer Res. 2009 Sep 1;69(17):6969-77. doi: 10.1158/0008-5472.CAN-09-0945. Epub 2009 Aug 18.

PMID:
19690138
[PubMed - indexed for MEDLINE]
Free Article
4.

 p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.

Sanhaji M, Kreis NN, Zimmer B, Berg T, Louwen F, Yuan J.

Cell Cycle. 2012 Feb 1;11(3):543-53. doi: 10.4161/cc.11.3.19076. Epub 2012 Feb 1.

PMID:
22262171
[PubMed - indexed for MEDLINE]
5.
6.

Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.

Zhou J, Gao Q, Chen G, Huang X, Lu Y, Li K, Xie D, Zhuang L, Deng J, Ma D.

Clin Cancer Res. 2005 Dec 1;11(23):8431-40.

PMID:
16322306
[PubMed - indexed for MEDLINE]
Free Article
7.

Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.

Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE.

Stem Cells. 2012 Jun;30(6):1064-75. doi: 10.1002/stem.1081.

PMID:
22415968
[PubMed - indexed for MEDLINE]
Free Article
8.

Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.

Lin YC, Sun SH, Wang FF.

Cell Signal. 2011 Nov;23(11):1816-23. doi: 10.1016/j.cellsig.2011.06.016. Epub 2011 Jun 29.

PMID:
21726628
[PubMed - indexed for MEDLINE]
9.

Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, Camphausen K.

Eur J Cancer. 2013 Sep;49(14):3020-8. doi: 10.1016/j.ejca.2013.05.013. Epub 2013 Jun 18.

PMID:
23790466
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.

Anticancer Drugs. 2011 Jun;22(5):444-53. doi: 10.1097/CAD.0b013e32834513f4.

PMID:
21399492
[PubMed - indexed for MEDLINE]
11.

Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.

Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R, Kaplan DR.

Cancer Res. 2011 Feb 15;71(4):1385-95. doi: 10.1158/0008-5472.CAN-10-2484. Epub 2011 Feb 8.

PMID:
21303981
[PubMed - indexed for MEDLINE]
Free Article
12.

TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.

Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E.

Mol Cancer Ther. 2012 Mar;11(3):700-9. doi: 10.1158/1535-7163.MCT-11-0762. Epub 2011 Dec 21.

PMID:
22188812
[PubMed - indexed for MEDLINE]
Free Article
13.

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.

Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR, Steeg PS.

Clin Cancer Res. 2009 Oct 1;15(19):6148-57. doi: 10.1158/1078-0432.CCR-09-1039. Epub 2009 Sep 29.

PMID:
19789319
[PubMed - indexed for MEDLINE]
Free Article
14.

Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).

Kreis NN, Sommer K, Sanhaji M, Krämer A, Matthess Y, Kaufmann M, Strebhardt K, Yuan J.

Cell Cycle. 2009 Feb 1;8(3):460-72. Epub 2009 Feb 18.

PMID:
19177004
[PubMed - indexed for MEDLINE]
Free Article
15.

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.

Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH, Foreman NK, Vibhakar R.

BMC Cancer. 2012 Mar 5;12:80. doi: 10.1186/1471-2407-12-80.

PMID:
22390279
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.

Danovi D, Folarin A, Gogolok S, Ender C, Elbatsh AM, Engström PG, Stricker SH, Gagrica S, Georgian A, Yu D, U KP, Harvey KJ, Ferretti P, Paddison PJ, Preston JE, Abbott NJ, Bertone P, Smith A, Pollard SM.

PLoS One. 2013 Oct 30;8(10):e77053. doi: 10.1371/journal.pone.0077053. eCollection 2013.

PMID:
24204733
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.

Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.

Cell Cycle. 2011 Apr 15;10(8):1303-11. Epub 2011 Apr 15.

PMID:
21436619
[PubMed - indexed for MEDLINE]
Free Article
18.

The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.

Russo MA, Kang KS, Di Cristofano A.

Thyroid. 2013 Oct;23(10):1284-93. doi: 10.1089/thy.2013.0037. Epub 2013 Jul 25.

PMID:
23509868
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.

Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, Zang JY, Liu Q, Su FX, Zhang P, Lieberman J, Wang J, Song E.

Sci Transl Med. 2012 Apr 18;4(130):130ra48. doi: 10.1126/scitranslmed.3003601.

PMID:
22517885
[PubMed - indexed for MEDLINE]
Free Article
20.

Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.

Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K.

Oncogene. 2007 Aug 23;26(39):5793-807. Epub 2007 Mar 19.

PMID:
17369857
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk